Abstracts Archive - Page 1439 of 2425 - ACR Meeting Abstracts

Abstract Number: 316 • 2016 ACR/ARHP Annual Meeting
Postural Stability Is Associated with Lower Pain, Lower Stiffness, and Higher Muscle Power Among Adults with Symptomatic Knee Osteoarthritis
Wei Liu¹, Augustine C. Lee², William F. Harvey², Lori Lyn Price³, Jeffrey B. Driban² and Chenchen Wang², ¹Osteopathic Rehabilitation and Biomechanics, 1Edward Via College of Osteopathic Medicine, Auburn, AL, USA, Auburn, AL, ²Rheumatology, Tufts Medical Center, Boston, MA, ³Clinical Care Research, Tufts Medical Center, Boston, MA
Background/Purpose: Postural stability is an indicator of static standing balance and a critical component of physical function and fall prevention among those with knee OA.…
Abstract Number: 317 • 2016 ACR/ARHP Annual Meeting
Leg Muscle Imbalance Is Associated with Radiographic Grade or Pain in Knee Osteoarthritis
Ji Yeon Lee¹, Kyungdo Han², Yong Gyu Park² and Sung-Hwan Park³, ¹International Healthcare Center, Seoul St Mary's Hosiptal, Seoul, Korea, Republic of, ²Department of Biostatistics, Catholic University of Korea, Seoul, South Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Osteoarthritis(OA) has been recognized as a progressive disease resulting from stress in synovial joint tissues including periarticular muscles. In knee OA, quadriceps muscle mass…
Abstract Number: 318 • 2016 ACR/ARHP Annual Meeting
Observer Variability of Joint Space with Measurements Is Subject Related in Medial Knee Osteoarthritis
Berna Goker¹, Seminur Haznedaroglu¹, Abdurrahman Tufan¹ and Joel Block², ¹Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Assessment of structural progression of knee osteoarthritis (OA) requires quantitative evaluation of the radiographic joint space width (JSW). Significant reduction in the rate…
Abstract Number: 319 • 2016 ACR/ARHP Annual Meeting
Incident Participation Restriction in Adults with Knee Osteoarthritis: Do Positive and Negative Affect Matter? the Multicenter Osteoarthritis Study
Molly Vaughan¹, David T. Felson², Michael P. Lavalley³, Gael Orsmond⁴, Jingbo Niu⁵, Cora E Lewis⁶, Neil Segal⁷, Michael Nevitt⁸ and Julie J. Keysor⁹, ¹635 Commonwealth Avenue, Room 651, Boston University College of Health & Rehabilitation Sciences, Boston, MA, ²Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Biostatistics, Boston University School of Public Health, Boston, MA, ⁴Department of Occupational Therapy, Boston University, Sargent College of Health & Rehabilitation Sciences, Boston, MA, ⁵Department of Nephrology, Baylor College of Medicine, Houston, TX, ⁶Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Kansas, Shawnee, KS, ⁸Department of Epidemiology & Biostatistics, University of California San Francisco School of Medicine, San Francisco, CA, ⁹Physical Therapy, Boston University, Boston, MA
Background/Purpose: Participation restrictions, common among people with knee osteoarthritis (OA), may be due to psychological factors. Many people with OA experience chronic pain, which can…
Abstract Number: 320 • 2016 ACR/ARHP Annual Meeting
The Value of Adjusting for Physical Activity When Measuring Osteoarthritis-Related Pain
Kelli Allen¹, Katherine Hall², Jennifer H. Lindquist³, Shannon Taylor⁴ and Cynthia Coffman⁵, ¹University of North Carolina at Chapel Hill and Durham VA Medical Center, Chapel Hill, NC, ²Durham VA Medical Center and Duke University Medical Center, Durham, NC, ³Health Services Research, Durham VA Medical Center, Durham, NC, ⁴Durham VA Medical Center, Durham, NC, ⁵Health Services Research, Durham VA Medical Center and Duke University Medical Center, Durham, NC
Background/Purpose: Measures of chronic pain typically do not account for individuals’ physical activity (PA) levels. Although PA is essential for managing conditions like osteoarthritis (OA),…
Abstract Number: 321 • 2016 ACR/ARHP Annual Meeting
Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis
EM Lewiecki¹, S Horlait², T Blicharski³, S Goemaere⁴, K Lippuner⁵, P Meisner⁶, PD Miller⁷, A Miyauchi⁸, J Maddox⁹, NS Daizadeh⁹ and A Grauer⁹, ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Amgen Ltd., Uxbridge, United Kingdom, ³Medical University of Lublin, Lublin, Poland, ⁴Ghent University Hospital, Gent, Belgium, ⁵Bern University Hospital, Bern, Switzerland, ⁶UCB Pharma, Brussels, Belgium, ⁷Colorado Center for Bone Research, Lakewood, CO, ⁸Miyauchi Medical Center, Osaka, Japan, ⁹Amgen Inc., Thousand Oaks, CA
Background/Purpose: Treatment with romosozumab (Romo) has been shown to rapidly increase BMD in postmenopausal women with low BMD through a dual effect on bone, increasing…
Abstract Number: 322 • 2016 ACR/ARHP Annual Meeting
The Activating Patients at Risk for Osteoporosis Study: A Randomized Trial within the Global Longitudinal Study of Osteoporosis in Women Cohort
Maria I. Danila¹, Ryan C. Outman¹, Elizabeth J. Rahn², Amy S. Mudano³, David T. Redden⁴, Peng Li⁴, Fred A. Anderson⁵, Julia P. Anderson⁶, Susan L. Greenspan⁷, Andrea Z. LaCroix^6,8, Jeri W. Nieves⁹, Stuart L. Silverman¹⁰, Ethel S. Siris¹¹, Nelson B. Watts¹², Michael J. Miller¹³, Jeffrey R. Curtis¹⁴, Amy H. Warriner³, Nicole C. Wright¹⁵ and Kenneth G. Saag¹⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Group Health Cooperative, Seattle, WA, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of California San Diego, La Jolla, CA, ⁹Helen Hayes, West Haverstraw, NY, ¹⁰Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹Columbia University Medical Center, New York, NY, ¹²Endocrinology, Diabetes & Metabolism, University of Cincinnati, Cincinnati, OH, ¹³University of Oklahoma, Tulsa, OK, ¹⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ¹⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To improve the rate of osteoporosis medication use in women with a prior fracture we developed and implemented a tailored, educational, direct-to-patient video intervention…
Abstract Number: 323 • 2016 ACR/ARHP Annual Meeting
Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the Freedom Extension Study
David W Dempster^1,2, NS Daizadeh³, A Fahrleitner-Pammer⁴, Jens-Erik Beck Jensen⁵, DL Kendler⁶, Ivo Valter⁷, Rachel B Wagman³, Susan Yue³ and Jacques P Brown⁸, ¹Columbia University, New York, NY, ²Helen Hayes Hospital, West Haverstraw, NY, ³Amgen Inc., Thousand Oaks, CA, ⁴Medical University, Graz, Austria, ⁵Hvidovre University Hospital, Hvidovre, Denmark, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷Center for Clinical and Basic Research, Tallinn, Estonia, ⁸Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada
Background/Purpose: Denosumab (DMAb) has been associated with low incidence of spine and non-spine, including hip, fractures through 10 years of treatment (Bone ASBMR 2015). Questions…
Abstract Number: 324 • 2016 ACR/ARHP Annual Meeting
A Placebo Controlled Trial of Vertebral Fill Technique Vertebroplasty for Acute Painful Osteoporotic Fracture (VAPOUR Trial)
Paul Bird^1,2, William Clark³, Terence Diamond⁴, Glen Schlaphoff⁵, Peter Smerdely⁶, Peter Gonski⁶ and Patrick McNeil⁷, ¹Medicine, University of New South Wales, Sydney, NSW, Australia, ²University of New South Wales, Sydney, Australia, ³Radiology, Southern Sydney Angiography, Sydney, Australia, ⁴Medicine, University of New South Wales, Sydney, Australia, ⁵Radiology, University of Sydney, Sydney, Australia, ⁶Aged Care, University of New South Wales, Sydney, Australia, ⁷Medicine, Macquarie University, Sydney, Australia
Background/Purpose: Evaluation of efficacy and safety of percutaneous vertebral fill technique vertebroplasty in subjects with acute vertebral fracture (symptom duration less than six weeks) .…
Abstract Number: 325 • 2016 ACR/ARHP Annual Meeting
Ebselen Is a Potential Anti-Osteoporosis Agent By Suppressing RANK Ligand-Induced Osteoclast Differentiation in Vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In Vivo
Changhoon Lee¹, Jong Min Baek², Ju-Young Kim², Won-Seok Lee³, Wan-Hee Yoo⁴, Myeung Su Lee⁵ and ACR authors group, ¹Division of Rheumatology, Department of Internal Medicine, Wonkwang University Hospital, Iksan, Korea, The Republic of, ²Department of Anatomy, School of Medicine, Wonkwang University, Iksan, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, jeonju, South Korea, ⁴Division of Rhuematology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, Jeonju, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Wonkwang University Hospital, Iksan, Chonbuk, South Korea
Background/Purpose: Ebselen is a non-toxic seleno-organic drug with anti-inflammatory and antioxidant properties that is currently being examined in clinical trials to prevent and treat various diseases,…
Abstract Number: 326 • 2016 ACR/ARHP Annual Meeting
Cortical Bone Changes in Pre- and Postmenopausal Healthy Women Measured with HR-pQCT
Jackeline Couto Alvarenga¹ and Rosa M R Pereira², ¹Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil
Background/Purpose: Increased fracture rates are well-recognized in adults with trabecular and cortical bone deficits, but cortical evaluation has been poorly studied. The aim of this…
Abstract Number: 327 • 2016 ACR/ARHP Annual Meeting
Drug Retention Rate of Oral Bisphosphonate in Patients with Rheumatoid Arthritis
Ji-Heh Park¹, Seung-Geun Lee¹, Eun-Kyoung Park², Hee-Sang Tag³ and Geun-Tae Kim⁴, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea, ⁴Kosin University College of Medicine, Busan, South Korea
Background/Purpose: As rheumatoid arthritis (RA) is a well-established risk factor for osteoporosis and compression fracture, non-adherence to bisphosphonate (BP) therapy in patients with RA can…
Abstract Number: 328 • 2016 ACR/ARHP Annual Meeting
A Study of Serum Electrolyte Levels after Denosumab Administration
KEN NAKASEKO, TAKAO SUDO and TAKAHIRO ASANO, KUWANA CITY MEDICAL CENTER, Kuwana Mie, Japan
Background/Purpose: Denosumab is an antiresorptive drug used for the treatement of postmenopausal osteoporosis. One of the major and critical adverse events of denosumab injection is…
Abstract Number: 329 • 2016 ACR/ARHP Annual Meeting
Explore the Possible Mechanisms of 1,25(OH)2D3 on the Formation of Osteoclasts in Rheumatoid Arthritis
Hong-yan WEN¹, Dan-dan LIU², Dan-dan WEI², Fang-fang ZHAO² and Xiao-feng LI², ¹Rheumatology, Shanxi Medical University, The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Shanxi Medical University, The Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: In our previous study, several conclusions are reached like: (1) IL-22 can promote inflammation and osteoclast formation in the process of RA;(2) 1,25(OH)2D3 decreases serum IL-22 level in RA patients, and acts as a…
Abstract Number: 330 • 2016 ACR/ARHP Annual Meeting
Safety of Denosumab in Postmenopausal Osteoporosis and in Cancer and Bone Metastase Treatment: A Systematic Review and Meta-Analysis
Marlène Aubailly¹, Bernard Combe², Cécile Gaujoux-Viala³, Cédric Lukas⁴, Jacques Morel⁵ and Hélène Che¹, ¹rheumatology, CHU Lapeyronie, University of Montpellier, France, ²Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ³CHU Nîmes, University of Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France
Background/Purpose: Denosumab is a RANK ligand antibody and the first biologic agent used for the treatment of post-menopausal osteoporosis (OP) and prevention of bone metastases…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].